# Mirxes

Source: https://onco.cc/companies/mirxes/  
OnCo record `mirxes` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Singapore microRNA diagnostics company with a stomach cancer blood test and a multi-cancer test in development.

## Summary

Mirxes sells GASTROClear, a microRNA blood test for gastric cancer that it reports holds FDA Breakthrough Device designation (August 2023) and NMPA approval (October 2025). Its multi-cancer screening test is in development through Project CADENCE (NCT05633342), launched in July 2022 for up to nine cancers using microRNA and DNA methylation; no multi-cancer results were found.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Singapore
- Type: diagnostics
- Website: https://mirxes.com/

## Sources

- Official website: https://mirxes.com/
- ClinicalTrials.gov NCT05633342: https://clinicaltrials.gov/study/NCT05633342

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- trials: [Project CADENCE (Mirxes multi-cancer blood test)](https://onco.cc/trials/cadence-mirxes/)

---
JSON: https://onco.cc/api/v1/entities/mirxes.json